RDO patient pathway improves operative rates in cataracts

Article

Operative rates for cataract surgery are higher for the refined direct optometrist (RDO) patient pathway, compared to the GP pathway, reveals a recent investigation in the UK.

Operative rates for cataract surgery are higher for the refined direct optometrist (RDO) patient pathway, compared to the GP pathway, reveals a recent investigation in the UK.

A retrospective cohort study led by Dr Kevin Holmes, Bristol, and the Plymouth Royal Eye Infirmary, Plymouth, UK, was conducted on 4657 patients referred to the “One-stop cataract clinic” at Bristol Eye Hospital between 1 November 2008 and 31 May 2010.

Of the patients in the cohort, 4222 were referred via the traditional GP route and 435 were referred via the new refined direct optometrist (RDO) route. The team compared the operative rate, which was identified as the conversion to surgery from referral.

Operative rates were higher for the RDO pathway, compared to the GP pathway at 91.9% and 82.4%, respectively. Combining referral information from optometrists and GPs creates a high-quality and efficient cataract surgery patient pathway.

Combining referral information also had major economic advantages and could be adopted at a national level in the UK.

The abstract can be found in the latest issue of the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.